The fusion peptide encoded by the KANSL1::ARL17A fusion transcript lacks some functional domains, and therefore, cancer patients expressing KANSL1::ARL17A display reduced activities of the histone acetyltransferase KAT8 and p53 [32–34]. This evidence concerns the gene TP53 and cancer.